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ABSTRACT 
Long acting muscarinic antagonists (LAMA) are currently considered the therapeutic mainstay 
for patients with COPD and have been shown to improve clinical outcomes including symptoms, 
exercise capacity and airflow limitation. Irisin, is a newly discovered hormone-like myokine 
generated by skeletal muscle cells in response to exercise and it is suggested to regulate energy 
expenditure and exercise capacity. The aim of the present study was to investigate if treatment 
with LAMA alters serum irisin levels in patients with COPD. Irisin was assessed by ELISA in the 
serum of 506 patients with COPD, GOLD II-IV, with a smoking history > 10 PY, who were 
included in the PROMISE-COPD cohort. The effect of inhaled LAMA on serum irisin levels was 
evaluated in a proof-of-concept cohort of 40 COPD patients.  
Univariate linear regression analysis revealed that there was a significant negative association of 
irisin with age-adjusted Charlson score (p = 0.003) and a positive association of irisin with 6-
min walking distance (6MWD) (p = 0.018) and treatment with LAMA (p = 0.004) but not with 
LABA or ICS. Multivariate analysis revealed that the association of irisin with LAMA treatment 
remains significant after adjustment for age-adjusted score and 6MWD. In the proof-of-concept 
cohort a single inhalation of LAMA stimulated serum irisin levels after 4h. 
These findings imply that treatment of COPD patients with LAMA increase circulating irisin, thus 
explaining some of the beneficial extra-pulmonary effects of these drugs when used in the 
treatment of COPD. 
ABBREVIATIONS: 6MWD, 6-min walking-distance; COPD, chronic obstructive pulmonary disease; LAMA, long acting 
muscarinic antagonists; FNDC5, fibronectin-type-III domain-containing protein-5; MMRC, Modified Medical Research 
Council Score; SGRQ, the St. George's Respiratory Questionnaire (SGRQ)-COPD version 
1 The two first authors contributed equally to the study. 
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Long-acting muscarinic antagonists (LAMA) in combination with long-acting beta2-agonists are 
increasingly being used to treat chronic obstructive pulmonary disease (COPD) due to greater 
improvement in lung function and symptom scores [1-5]. Both classes of bronchodilators relax 
airway smooth muscle and thereby reduce respiratory muscle activity and dynamic 
hyperinflation and improve ventilatory mechanics [6-8]. In patients with COPD, the use of LAMA, 
as compared to placebo, reduced lung hyperinflation and inspiratory capacity at rest and during 
exercise contributing to improvement in exertional dyspnea and increased exercise endurance 
[8]. Beside their bronchodilatory effects, LAMA, as compared with LABA, have been shown to 
exert superior anti-inflammatory activity reducing the production of superoxide and pro-
inflammatory mediators in COPD patients [9]. However, the beneficial effects of LAMA for COPD 
patients cannot be based solely on their bronchodilatory and their anti-inflammatory actions 
[10-12]. LAMA have been shown to increase exercise endurance in patients with COPD, with an 
as yet unknown mechanism, other than reduction of lung hyperinflation [13]. 
Irisin is a newly described myokine generated by the degradation of the muscle cell protein 
assigned as fibronectin type III domain-containing protein 5 (FNDC5) [14,15]. FNDC5 
expression and serum irisin are increased by exercise and therefore both proteins are regarded 
as indicators for increased muscle activity and improved endurance [16,17]. In COPD, serum 
irisin has been correlated with exercise capacity [18,19]. Additional factors, such as diet or 
insulin metabolism, have been shown to be dominant regulators of irisin release, while gender 
and age are less important [20]. 
In the present study, we investigated if treatment with LAMA alters serum levels of irisin in a 
cohort of 506 COPD patients. We further explored the effect of LAMA on irisin regulation in a 
proof-of-concept cohort of 40 COPD patients. 
 
Methods 
STUDY DESIGN, PATIENTS 
The study cohort consisted of 638 patients enrolled in the "PRedicting Outcome using systemic 
Markers In Severe Exacerbations of Chronic Obstructive Pulmonary Disease" (PROMISE-COPD) 
study, a multicenter study in 11 centers in 8 European countries. The PROMISE-COPD study was 
designed to be inclusive, exploratory and hypothesis generating. It was specifically drafted to 
identify predictors of outcome using systemic markers in patients with moderate to very severe 
COPD [forced expiratory volume in 1 s (FEV1) less than 80% of predicted value after 
bronchodilator use and a ratio of FEV1 to forced vital capacity (FVC) of 0.7 or less after 
bronchodilator use (grade II-IV)], based on physical examination and spirometry, at least 4 
weeks after the latest exacerbation was resolved. All patients were older than 40 years, current 
or ex-smokers with a smoking history of ≥10 pack-years. Exclusion criteria were rapid fatal 
disease with death expected within 6 months, pulmonary condition other than COPD as the main 
respiratory disease, immunosuppression including organ transplantation or chronic steroid use 
(> 20 mg prednisolone equivalent per day) and muscle-skeletal or neuromuscular process 
preventing ambulation. 
All enrolled patients had an initial baseline examination at stable state and were followed up for 
at least two years in scheduled visits every six months. When necessary, patients underwent 
outpatient visits or were hospitalized for treatment of AECOPD, and follow up visits were 
performed 4 weeks after the onset of exacerbation. 
Throughout the study duration, patients were treated as clinically warranted, without 
restriction. Patients were monitored for recurrent moderate (requiring treatment with 
Published in : Pulmonary Pharmacology and Therapeutics (2018), vol. 48, pp. 111–116 
DOI: https://doi.org/10.1016/j.pupt.2017.10.011 
Status : Postprint (Author’s version)   
 
 
systematic corticosteroids, antibiotics, or both) and severe AECOPD (requiring hospitalization 
or a visit to the emergency department). COPD exacerbation was defined as an acute change 
from baseline in dyspnea, cough, and/or sputum production beyond normal day-to-day 
variation that necessitates use of antibiotics, glucocorticoids, or both. 
Clinical history, physical examinations, lung function, and 6-min walking test (6MWT) were 
performed for each patient. The age-adjusted Charlson Comorbidity Index Score was also 
calculated. Each patient also completed the Modified Medical Research Council Score (MMRC), 
the St. George's Respiratory Questionnaire (SGRQ)-COPD version and the Short Form-36 (SF-36) 
health related, quality of life questionnaire. All examinations took place at each scheduled visit 
(semi-annually), except for the 6MWT. At the 2-year follow up, the vital status of each patient 
was confirmed. 
We also included a proof-of-concept cohort of 40 COPD patients who participated in the N2COPD 
Washout study (N2 washout for evaluation of small airway involvement in COPD) [21], to test 
the effect of LAMA inhalation on serum irisin levels. These patients did not receive treatment 
with LAMA for 24 h or 48 h and then they inhaled a single dose of LAMA (glycopyrronium 44 
mcg or tiotropium, 18 mcg). Serum samples were collected before and then 1 h and 4 h after the 
inhalation of LAMA. 
The PROMISE-COPD study and the N2COPD Washout study were investigator-initiated and 
driven studies compiled with the Helsinki Declaration and GCP Guidelines, and were approved 
by the Institutional review Board (EKBB295/07 and EKNZ340/13, respectively). The PROMISE-
COPD study was registered at www.controlled-trials.com (identifier ISRCTN99586989). All 
patients provided written consent for the study assessments. 
DETERMINATION OF IRISIN 
Serum irisin was determined by ELISA (Adipogen, Liestal, Switzerland). All samples were 
assayed in duplicate. 
Statistics: For the patient cohort, the Null-hypothesis was that there was no difference of serum 
irisin between patient groups, clinical parameters or treatment. The data were compared using a 
computer assisted statistic program SPSS (version 220 for Macintosh, IBM, Switzerland). For all 
statistics p-value < 0.05 was considered as significant. Continuous variables are expressed as 
the mean ± SD or median (interquartile range: 25th to 75th percentile) and discrete variables as 
percentage. Linear univariate and multivariate regression model analysis was applied to 
evaluate the relationship between irisin and clinically relevant variables in COPD. 
Results 
PATIENTS 
From the 638 patients that were enrolled in the study, a total of 506 patients attended a 
scheduled visit at 6 months. These patients were followed-up for a period of 722 [395-762] days. 
During the follow-up, 317 patients (62.6%) suffered from one or more exacerbations (354 
exacerbations in total) and 38 patients (7.5%) deceased (Fig. 1). 
Most patients in the PROMISE-COPD cohort were male, with a considerable smoking history and 
clinically relevant disease (1 exacerbation requiring physician attention in the previous year) 
(Table 1) and multiple comorbidities (online Table 1). Characteristics of the 354 exacerbations 
are presented in online Table 2. 
ASSOCIATION OF SERUM IRISIN WITH BASELINE DEMOGRAPHIC AND CLINICAL 
CHARACTERISTICS 
Univariate linear regression analysis revealed that serum irisin was inversely associated with 
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age-adjusted Charlson score (p = 0.003) and positively correlated with: (a) 6MWD (p = 0.018); 
(b) the emotional role in SF-36 questionnaire (p = 0.034) and (c) treatment of patients with 
LAMA (p = 0.004) (Table 2). The association of irisin with the age-adjusted score and LAMA 
remained significant (p = 0.008 and p = 0.001, respectively) after adjustment for 6MWD and 
emotional role in the SF-36 questionnaire, as revealed by multivariate linear regression analysis 
(Table 3). 
LAMA INCREASE SERUM IRISIN 
Patients with stable COPD, who were receiving LAMA, had higher levels of irisin (median: 1.4 ± 
0.1 µg/ml), as compared with patients who were not receiving LAMA (median: 1.0   ±  0.1 
µg/ml) (p  <  0.001) (Fig. 2). 
To validate the effect of LAMA on serum irisin levels, we measured irisin in the serum of 40 
COPD patients, with stable disease, who were included in the proof-of-concept cohort. The 
baseline characteristics of these patients are presented in Table 4. Patients were instructed to 
stop the inhalation of LAMA for 24 h (n = 23) or 48 h (n = 17) prior the experiment (Fig. 3). 
Serum irisin was determined before LAMA inhalation, and 1 h and 4 h after a single inhalation of 
LAMA. In patients that were on 24-h LAMA withdrawal, we did not observe any effect of LAMA 
on serum irisin levels neither 1 h nor 4 h after LAMA inhalation. However, in patients that did 
not receive LAMA for 48 h, serum irisin was not altered 1 h after LAMA inhalation but increased 
significantly 4 h after LAMA inhalation (p = 0.047) (Fig. 4). 
Fig. 1. Strengthening the Reporting of Observational studies in Epidemiology (STROBE) flow 
chart for the patients in the PROMISE-COPD cohort. PROMISE-COPD: Predicting Outcome Using 
Systemic Markers in Severe Exacerbations of Chronic Obstructive Pulmonary Disease; GOLD: 
Global Initiative for Chronic Obstructive Lung Disease. 
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Irisin is a recently described myokine, mainly released by SkMC, which has been proposed to 
mediate the beneficial effects of exercise [14,22, 23]. Up to date, there is very limited evidence 
regarding the role of irisin in COPD [18,19,24]. In the present study, serum irisin levels were 
assessed in a large cohort of 506 patients with COPD, at stable state and at exacerbation. The 
data provide evidence, for the first time, that serum irisin in COPD patients at stable state, was 
inversely associated with the age-adjusted Charlson score, while positively associated with the 
6MWD and treatment with LAMA. Furthermore, in a proof-of-concept cohort, it was 
demonstrated that inhalation of LAMA increased serum irisin in COPD patients. 
In COPD patients at stable state, serum irisin was inversely associated with age-adjusted 
Charlson score, indicating that low serum irisin levels are related with the number and severity 
of comorbidities. The most common comorbidity was arterial hypertension (50.6% of the 
patients), followed by coronary arterial disease (22.5%), congestive heart failure (15%) and 
diabetes mellitus (12.3%). Previous studies have shown a negative association between 
circulating irisin levels and type-2 diabetes mellitus [25,26]. However, the regulation of irisin in 
humans, as well as the role of irisin in glucose metabolism remains unclear, with conflicting 
results for the association of irisin and glucose levels, insulin levels, and insulin resistance 
[26,27]. 
Serum irisin levels at stable state did not correlate with age, BMI or with BODE index, which is in 
agreement with a study showing that serum irisin concentration did not correlate with age, BMI, 
glucose, insulin, lipoproteins, cholesterol metabolism or adipokines [28]. In our cohort, serum 
irisin was associated with 6MWD, indicating that high serum irisin is related to exercise capacity 
in COPD patients. Multivariate analysis showed that the association of irisin with 6MWD was lost 
when adjusted for the age-adjusted Charlson score, indicating that comorbidities have a greater 
impact on exercise capacity in COPD patients. Exercise has been associated with increased irisin 
levels [29]. Greulich et al. [24] showed that whole body vibration exercise in hospitalized 
patients with COPD was associated with increased levels of irisin and improvement in 6MWD 
whereas in the study of Ijiri et al., it was demonstrated that acute exercise did not affect serum 
irisin, but eight-week exercise training was linked to significant increase in its levels [18]. 
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Table 1. Baseline characteristics of 506 patients with COPD GOLD II-IV, at stable state, included 
in the PROMISE-COPD cohort. 
Characteristics n = 506 
Age, years 66.8   ±   10.5 
Gender, Male, No. (%) 366 (71.9) 
BMI, kg/m2 26.2   ±   5.5 
Weight, kg 74.9   ±   17.0 
Height, cm 169.0   ±   8.0 
White, yes (%) 501 (99.0) 
Current smoker no. (%) 150 (29.6) 
Pack-years, years 51.5   ±   30.9 
Duration of COPD symptoms, months 102.7   ±   89.1 
Time elapse since diagnosis, months 80.2   ±   74.6 
MMRC dyspnea scale 1 [1-2] 
BODE index 3 [1-4] 
6MWD, meters 380.3   ±   104.2 
Borg Score 4 [3-6] 
SaO2 at rest, % 94.5   ±   2.7 
Lowest SaO2 at exercise, % 89.5   ±   5.7 
Heart rate at rest, bpm 80.4   ±   14.5 
Highest heart rate at rest, bpm 104.8   ±   18.4 
SGRQ  
Symptoms score 49.0   ±   22.7 
Activity score 57.4   ±   22.8 
Impact score 32.2   ±   18.7 
Total Score 42.4   ±   18.1 
SF-36  
Physical function 51.4   ±   25.9 
Role Physical 51.7   ±   43.5 
Role emotional 67.5   ±   42.9 
Social functioning 69.8   ±   28.2 
Mental health 65.4   ±   19.8 
Body pain 73.9   ±   27.6 
Vitality 51.9   ±   20.9 
General Health 48.2   ±   23.1 
GOLD gradea, n %                                         253 (50.0) 
II 
III 177 (35.0) 
IV 76 (15.0) 
FVC, post-brd, % predicted 77.8   ±   24.8 
FEV1; post-brd, %predicted 48.6   ±   18.2 
FEV1/FVC post-brd, % 48.2   ±   14.1 
Residual volume (RV), % 157.4   ±   45.6 
Total lung capacity (TLC), % 118.8   ±   20.21 
RV/TLC, % 53.7   ±   9.6 
Diffusion capacity (DLCO), % 55.6   ±   20.7 
Arterial blood gas analysis  
PaO2, mm Hg 69.0   ±   51.8 
PaCO2, mm Hg 39.8   ±   6.8 
Therapy for COPD  
LAMA 343 (67.7) 
LABA 369 (72.9) 
ICS 402 (79.4) 
Systemic glucocorticoids 22 (4.3) 
Continuous data are shown as mean ± SD or median IQR, and categorical variables as No. (%). BMI: body mass index; 
Age-adjusted score: Age-adjusted Charlson Comorbidity score; 6MWD: 6-min walk distance; bpm: beats/min; brd: 
bronchodilator; DLCO: Diffusion capacity of the lung for carbon monoxide; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; ICS: Inhaled corticosteroids; MMRC: modified Medical Research Council; LABA: Long-acting 
beta2-agonist; LAMA: Long-acting muscarinic antagonists; PaCO2: Carbon dioxide pressure; PaO2: Oxygen pressure; 
SABA: short-acting beta2-agonist; SaO2: Peripheral oxygen saturation; SF-36: Short Form-36; SGRQ: St. George's 
Respiratory Questionnaire. 
a GOLD grades are based on FEV1% predicted: II, > 50% < 80%; III > 30% < 50%; IV, < 30%. There were no patients 
with GOLD grade I COPD because of study inclusion criteria. 
Table 2. Univariate linear regression analysis for the association of serum levels of irisin with 
different treatments in patients with COPD (n = 506), included in the PROMISE-COPD cohort. 
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Log IRISIN β 95% CI P value 
LABA -0.218 -0.963-0.527 0.566 
LAMA 0.861 0.279-1.442 0.004 
ICS -0.329 -1.025-0.367 0.353 
Systemic steroids 0.066 -1.258-1.390 0.922 
LABA: Long-acting beta2-agonist; LAMA: Long-acting muscarinic antagonists; ICS: inhaled corticosteroids. 
 
Table 3. Multivariate linear regression model for the association of irisin with COPD 
characteristics in a cohort of 506 patients included in the PROMISE study. 
Variable β p value 
Age-adjusted Charlson score -0.248 (-0.430--0.066) 0.008 
6 min walking distance 0.002 (-0.001-0.005) 0.142 
Role emotional 0.004 (-0.003-0.010) 0.258 
Treatment with LAMA 0.967 (0.376-1.559) 0.001 
LAMA: Long-acting muscarinic antagonists. 
 
Fig. 2. Serum irisin levels in COPD patients at stable state who were not receiving LAMA (n = 
152) and who were receiving LAMA (n = 354). 
 
 
Table 4. Baseline characteristics of 40 patients with COPD GOLD II-IV, at stable state, included in 
the proof-of-concept cohort. 
Characteristics  n = 40 
Age, years  66.7  ±  16.0 
Gender, Male, No. (%)  25 (62.5) 
Weight, kg  74.9  ±  17.0 
Height, cm  166.8  ±  8.3 
GOLD gradea, n % I 2 (5.0) 
 II 26 (65.0) 
 III 12 (30.0) 
FVC, post-brd, % predicted  86.4  ±  16.7 
FEV1, post-brd, %predicted  56.1  ±  15.6 
FEV1/FVC post-brd, %  47.4  ±  11.3 
Residual volume (RV), %  144.5  ±  41.5 
Total lung capacity (TLC), %  107.7  ±  18.5 
RV/TLC, %  51.7  ±  9.4 
Diffusion capacity (DLCO), %  59.9  ±  15.8 
Continuous data are shown as mean ± SD or median IQR, and categorical variables as No. (%). GOLD: Global Initiative 
for Chronic Obstructive Lung Disease. 
a GOLD grades are based on FEV1% predicted: I > 80%; II > 50%   <   80%; III > 30%   <   50%. 
In this study, serum irisin was associated with treatment of patients with LAMA and this 
association remained significant after adjustment for other factors that were also associated 
with irisin such as the age-adjusted Charlson score, 6MWD and the emotional role in the SF-36 
questionnaire. LAMA belongs to first-line treatment in patients with COPD with proven 
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beneficial therapeutic outcomes.  In this study, treatment with LAMA, but not with any other 
medication for COPD, was associated with serum irisin levels. Patients with stable COPD, who 
were receiving LAMA, had higher serum levels of irisin, as compared with patients who were not 
receiving LAMA. Despite the fact that there is an overlap of irisin values between the two groups 
of patients, the fact that: (a) measurements were always performed in duplicate; (b) the large 
number of patients in each group (354 patients that were receiving LAMA and 152 patients that 
were not receiving LAMA) and (c) the high intra-assay and inter-assay precisions, with 
coefficient of variation 5.7% and 9.6%, respectively, convinces for the robustness of the assay. 
This is the first time that the effect of LAMA on irisin has been investigated in vivo, in a small 
proof-of-concept cohort, including 40 COPD patients. The inhalation of LAMA increased serum 
irisin between one and four hours after inhalation. This effect was significant only in patients 
that did not inhale LAMA for 48 h prior the experimental administration of LAMA, indicating that 
the effect of LAMA on irisin secretion remains for longer than 24 h. These findings fit very well 
with the recent documentation that treatment with tiotropium, at a daily dose of 5 µg, resulted 
in a significant improvement in exercise tolerance in patients with moderate COPD, while 
treatment with indacaterol, at a daily dose of 150 µg, did not, although no significant differences 
were observed between the two treatments regarding their effects on lung hyperinflation, 
exercise-related dyspnea, and daily-life dyspnea [13]. This clearly indicates that other 
mechanisms than sustained reductions of lung hyperinflation should be considered to explain 
improved exercise tolerance after treatment with LAMA. Since it was shown that serum irisin 
levels were associated with the level of physical activity in COPD patients, and that an eight-
week exercise training was linked to a significant increase in irisin level [18], the increased 
serum irisin levels after a single inhalation of LAMA documented in the present study may be 
considered the piece of information missing. 
Fig. 3. Strengthening the Reporting of Observational studies in Epidemiology (STROBE) flow 
chart for the patients in the proof-of-concept cohort. GOLD: Global Initiative for Chronic 
Obstructive Lung Disease. 
 
 
COPD is associated with various extra-pulmonary manifestations including cachexia and muscle 
atrophy [30]. It has been shown that skeletal muscle functions like strength and endurance, as 
well as muscle structure like fibre quality, capillary density and metabolic capacity, are altered in 
patients with COPD [31]. Furthermore, it has been shown that during acute exacerbations, the 
anabolic-catabolic ratio is shifted towards the catabolic state of the muscle, which is 
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accompanied by ischemia-related apoptosis injury [30]. Considering that irisin increases total 
body energy expenditure and resistance to obesity-linked insulin resistance [26] and that 
administration of irisin has been proposed as a potential therapeutic target to treat obesity and 
diabetes, it may be postulated that the stimulatory effect of LAMA on irisin release observed in 
vivo and in vitro in this study, underlines an additional beneficial effect of LAMA in mediating 
metabolic restoration and increasing exercise capacity in COPD patients. 
Fig. 4. Serum irisin levels in COPD patients, at stable state, who did not receive LAMA for 48 h (n 
= 17), 1 h and 4 h after a single dose of LAMA inhalation. Results are presented as % over 
baseline value that is irisin levels before the LAMA inhalation, p-value was calculated by the 
Friedman test for all three values. 
 
The present study must be interpreted within the context of certain limitations. In the proof-of-
concept cohort, cessation of LAMA treatment for 24 and 48 h was probably inadequate to 
achieve total wash out of the drugs. However, the fact that we observed a significant increase of 
irisin, 4 h after the administration of LAMA, as compared to baseline that was under the 
influence of the remaining LAMA, indicates that our conclusion for the significant stimulation of 
irisin by LAMA is solid. It remains to be established whether the magnitude of irisin increase 
after LAMA inhalation is associated with the clinical improvement or COPD prognosis. 
Nevertheless, the current data suggest a so far unrevealed extra-pulmonary mechanism 
mediating the action of LAMA in COPD. 
In conclusion, treatment with LAMA increases serum irisin by a mechanism that involves 
shedding from its precursor molecule FNDC5 and this may mediate the additional beneficial 
effects of LAMA in COPD. 
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